Skip to main content
Erschienen in: World Journal of Pediatrics 1/2022

20.11.2021 | Meta-analysis

Risk factors for Clostridioides difficile infection in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysis

verfasst von: Sheng-Bo Fang, Yan-Qing Song, Chun-Yan Zhang, Li-Bo Wang

Erschienen in: World Journal of Pediatrics | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Risk factors and consequences associated with Clostridioides difficile infection (CDI) in children and adolescents with inflammatory bowel disease (IBD) are still uncertain. We conduct a systematic review and meta-analysis to assess risk factors and outcomes associated with CDI in children and adolescents with IBD.

Methods

PubMed, EMBASE and Cochrane Library databases were searched from inception to 24th February, 2021. Studies investigating risk factors, bowel surgery rate in pediatric IBD patients with and without CDI were included. Random-effects model was used for calculating summary estimates. Newcastle–Ottawa scale (NOS) was used for quality assessment.

Results

Fourteen studies, comprising 17,114 patients, were included. There was a significant association between 5-aminosalicylic acid (5-ASA) use and CDI [odds ratio (OR) = 1.95, 95% confidence interval (CI) 1.26–3.03], with minimal heterogeneity (I2 = 0.00%). Increased risk of active disease (OR = 4.66, 95% CI 2.16–10.07) were associated with CDI in those studies performed in high quality score (NOS > 6) and significantly higher CDI rates in studies conducted outside USA (OR = 2.94, 95% CI 1.57–5.58). The bowel surgery rate in IBD with CDI was 3.8–57.1%, compared to that in IBD without CDI (0–21.3%). All studies were of moderate to high quality.

Conclusions

5-ASA use and active disease might be risk factors associated with CDI in children and adolescents with IBD. Bowel surgery rates associated with CDI in IBD patients varied greatly. Large-scale clinical studies on CDI in children and adolescents with IBD are still needed to verify risk factors and outcomes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204–10.PubMedCrossRef McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204–10.PubMedCrossRef
2.
Zurück zum Zitat Noor A, Krilov LR. Clostridium difficile infection in children. Pediatr Ann. 2018;47:e359–65.PubMedCrossRef Noor A, Krilov LR. Clostridium difficile infection in children. Pediatr Ann. 2018;47:e359–65.PubMedCrossRef
3.
Zurück zum Zitat Banaszkiewicz A, Pituch H. Clostridium difficile infection in children with inflammatory bowel disease: current evidence. Curr Pharm Des. 2014;20:4549–55.PubMedCrossRef Banaszkiewicz A, Pituch H. Clostridium difficile infection in children with inflammatory bowel disease: current evidence. Curr Pharm Des. 2014;20:4549–55.PubMedCrossRef
4.
Zurück zum Zitat Pascarella F, Martinelli M, Miele E, Del Pezzo M, Roscetto E, Staiano A. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr. 2009;154:854–8.PubMedCrossRef Pascarella F, Martinelli M, Miele E, Del Pezzo M, Roscetto E, Staiano A. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr. 2009;154:854–8.PubMedCrossRef
5.
Zurück zum Zitat Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976–83.PubMedCrossRef Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976–83.PubMedCrossRef
6.
Zurück zum Zitat Mezoff E, Mann EA, Hart KW, Lindsell CJ, Cohen MB. Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population. J Pediatr Gastroenterol Nutr. 2011;52:437–41.PubMedPubMedCentralCrossRef Mezoff E, Mann EA, Hart KW, Lindsell CJ, Cohen MB. Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population. J Pediatr Gastroenterol Nutr. 2011;52:437–41.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Wultańska D, Banaszkiewicz A, Radzikowski A, Obuch-Woszczatyński P, Młynarczyk G, Brazier JS, et al. Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease. Eur J Clin Microbiol Infect Dis. 2010;29:1265–70.PubMedPubMedCentralCrossRef Wultańska D, Banaszkiewicz A, Radzikowski A, Obuch-Woszczatyński P, Młynarczyk G, Brazier JS, et al. Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease. Eur J Clin Microbiol Infect Dis. 2010;29:1265–70.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Kelsen JR, Kim J, Latta D, Smathers S, McGowan KL, Zaoutis T, et al. Recurrence rate of Clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:50–5.PubMedCrossRef Kelsen JR, Kim J, Latta D, Smathers S, McGowan KL, Zaoutis T, et al. Recurrence rate of Clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:50–5.PubMedCrossRef
9.
Zurück zum Zitat Pant C, Anderson MP, Deshpande A, Altaf MA, Grunow JE, Atreja A, et al. Health care burden of Clostridium difficile infection in hospitalized children with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1080–5.PubMedCrossRef Pant C, Anderson MP, Deshpande A, Altaf MA, Grunow JE, Atreja A, et al. Health care burden of Clostridium difficile infection in hospitalized children with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1080–5.PubMedCrossRef
10.
Zurück zum Zitat Banaszkiewicz A, Kowalska-Duplaga K, Pytrus T, Pituch H, Radzikowski A. Clostridium difficile infection in newly diagnosed pediatric patients with inflammatory bowel disease: prevalence and risk factors. Inflamm Bowel Dis. 2012;18:844–8.PubMedCrossRef Banaszkiewicz A, Kowalska-Duplaga K, Pytrus T, Pituch H, Radzikowski A. Clostridium difficile infection in newly diagnosed pediatric patients with inflammatory bowel disease: prevalence and risk factors. Inflamm Bowel Dis. 2012;18:844–8.PubMedCrossRef
11.
Zurück zum Zitat Kim DH, Cho JM, Yang HR. Clostridium difficile infection at diagnosis and during the course of paediatric inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr. 2018;21:43–50.PubMedPubMedCentralCrossRef Kim DH, Cho JM, Yang HR. Clostridium difficile infection at diagnosis and during the course of paediatric inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr. 2018;21:43–50.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Chandrakumar A, Zohni H, El-Matary W. Clostridioides difficile infection in children with inflammatory bowel disease. Inflamma Bowel Dis. 2020;26:1700–6.CrossRef Chandrakumar A, Zohni H, El-Matary W. Clostridioides difficile infection in children with inflammatory bowel disease. Inflamma Bowel Dis. 2020;26:1700–6.CrossRef
13.
Zurück zum Zitat Krishnarao A, de Leon L, Bright R, Moniz H, Law M, Leleiko N, et al. Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting. Inflamma Bowel Dis. 2015;21:564–9.CrossRef Krishnarao A, de Leon L, Bright R, Moniz H, Law M, Leleiko N, et al. Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting. Inflamma Bowel Dis. 2015;21:564–9.CrossRef
14.
Zurück zum Zitat Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol. 2010;16:4892–904.PubMedPubMedCentralCrossRef Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol. 2010;16:4892–904.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Nitzan O, Elias M, Chazan B, Raz R, Saliba W. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. World J Gastroenterol. 2013;19:7577–85.PubMedPubMedCentralCrossRef Nitzan O, Elias M, Chazan B, Raz R, Saliba W. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. World J Gastroenterol. 2013;19:7577–85.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Balram B, Battat R, Al-Khoury A, D’Aoust J, Afif W, Bitton A, et al. Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2019;13:27–38.PubMedCrossRef Balram B, Battat R, Al-Khoury A, D’Aoust J, Afif W, Bitton A, et al. Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2019;13:27–38.PubMedCrossRef
17.
Zurück zum Zitat Hojsak I, Ferenc T, Bojanić K, Mišak Z, Močić Pavić A, Lukić-Grlić A, et al. Incidence of Clostridium difficile infection in children with inflammatory bowel disease compared to oncology and immunocompetent patients. Digestion. 2012;86:6–11.PubMedCrossRef Hojsak I, Ferenc T, Bojanić K, Mišak Z, Močić Pavić A, Lukić-Grlić A, et al. Incidence of Clostridium difficile infection in children with inflammatory bowel disease compared to oncology and immunocompetent patients. Digestion. 2012;86:6–11.PubMedCrossRef
18.
Zurück zum Zitat Mir SAV, Kellermayer R. Clostridium difficile infection in newly diagnosed pediatric inflammatory bowel disease in the mid-southern United States. J Pediatr Gastroenterol Nutr. 2013;57:487–8.PubMedPubMedCentralCrossRef Mir SAV, Kellermayer R. Clostridium difficile infection in newly diagnosed pediatric inflammatory bowel disease in the mid-southern United States. J Pediatr Gastroenterol Nutr. 2013;57:487–8.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Martinelli M, Strisciuglio C, Veres G, Paerregaard A, Pavic AM, Aloi M, et al. Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN study. Inflamma Bowel Dis. 2014;20:2219–25.CrossRef Martinelli M, Strisciuglio C, Veres G, Paerregaard A, Pavic AM, Aloi M, et al. Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN study. Inflamma Bowel Dis. 2014;20:2219–25.CrossRef
20.
Zurück zum Zitat Hellmann J, Andersen H, Fei L, Linn A, Bezold R, Lake K, et al. Microbial shifts and shorter time to bowel resection surgery associated with C. difficile in pediatric Crohn’s disease. Inflamm Bowel Dis. 2020;26:1212–21.PubMed Hellmann J, Andersen H, Fei L, Linn A, Bezold R, Lake K, et al. Microbial shifts and shorter time to bowel resection surgery associated with C. difficile in pediatric Crohn’s disease. Inflamm Bowel Dis. 2020;26:1212–21.PubMed
21.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9, W64.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9, W64.CrossRef
23.
Zurück zum Zitat Deeks JJ, Higgins JPT, Altman DG, editors. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.2 (updated Feb 2021). Cochrane. 2021. www.training.cochrane.org/handbook. Accessed 1 Jun 2020. Deeks JJ, Higgins JPT, Altman DG, editors. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.2 (updated Feb 2021). Cochrane. 2021. www.​training.​cochrane.​org/​handbook. Accessed 1 Jun 2020.
25.
Zurück zum Zitat Hourigan SK, Oliva-Hemker M, Hutfless S. The prevalence of Clostridium difficile infection in pediatric and adult patients with inflammatory bowel disease. Dig Dis Sci. 2014;59:2222–7.PubMedCrossRef Hourigan SK, Oliva-Hemker M, Hutfless S. The prevalence of Clostridium difficile infection in pediatric and adult patients with inflammatory bowel disease. Dig Dis Sci. 2014;59:2222–7.PubMedCrossRef
26.
Zurück zum Zitat Li D, Guo S, Guan DX, Zhao CN, Xu XW. Infection rate and clinical characteristics of toxigenic Clostridium difficile in children with inflammatory bowel disease. Zhonghua Er Ke Za Zhi. 2020;58:564–9 (in Chinese).PubMed Li D, Guo S, Guan DX, Zhao CN, Xu XW. Infection rate and clinical characteristics of toxigenic Clostridium difficile in children with inflammatory bowel disease. Zhonghua Er Ke Za Zhi. 2020;58:564–9 (in Chinese).PubMed
27.
Zurück zum Zitat Hyams JS, McLaughlin JC. Lack of relationship between Clostridium difficile toxin and inflammatory bowel disease in children. J Clin Gastroenterol. 1985;7:387–90.PubMedCrossRef Hyams JS, McLaughlin JC. Lack of relationship between Clostridium difficile toxin and inflammatory bowel disease in children. J Clin Gastroenterol. 1985;7:387–90.PubMedCrossRef
28.
Zurück zum Zitat Lamousé-Smith ESN, Weber S, Rossi RF, Neinstedt LJ, Mosammaparast N, Sandora TJ, et al. Polymerase chain reaction test for Clostridium difficile toxin B gene reveals similar prevalence rates in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;57:293–7.PubMedCrossRef Lamousé-Smith ESN, Weber S, Rossi RF, Neinstedt LJ, Mosammaparast N, Sandora TJ, et al. Polymerase chain reaction test for Clostridium difficile toxin B gene reveals similar prevalence rates in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;57:293–7.PubMedCrossRef
29.
Zurück zum Zitat Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, Part 1: ambulatory care-an evidence-based guideline from European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:257–91.PubMedCrossRef Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, Part 1: ambulatory care-an evidence-based guideline from European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:257–91.PubMedCrossRef
30.
Zurück zum Zitat Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–207.PubMedCrossRef Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–207.PubMedCrossRef
31.
Zurück zum Zitat Stevens C, Lipman M, Fabry S, Moscovitch-Lopatin M, Almawi W, Keresztes S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther. 1995;272:399–406.PubMed Stevens C, Lipman M, Fabry S, Moscovitch-Lopatin M, Almawi W, Keresztes S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther. 1995;272:399–406.PubMed
32.
Zurück zum Zitat MacDermott RR, Schloemann SR, Bertovich MJ, Nash GS, Peters M, Stenson WF. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology. 1989;96:442–8.PubMedCrossRef MacDermott RR, Schloemann SR, Bertovich MJ, Nash GS, Peters M, Stenson WF. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology. 1989;96:442–8.PubMedCrossRef
33.
Zurück zum Zitat Gong SS, Fan YH, Han QQ, Lv B, Xu Y. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. World J Gastroenterol. 2019;25:2240–50.PubMedPubMedCentralCrossRef Gong SS, Fan YH, Han QQ, Lv B, Xu Y. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. World J Gastroenterol. 2019;25:2240–50.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Vitikainen K, Haapamäki J, Färkkilä M, Anttila VJ, Arkkila P. Clostridium difficile infection in patients with inflammatory bowel disease: a case control study. Scand J Gastroenterol. 2018;53:947–51.PubMedCrossRef Vitikainen K, Haapamäki J, Färkkilä M, Anttila VJ, Arkkila P. Clostridium difficile infection in patients with inflammatory bowel disease: a case control study. Scand J Gastroenterol. 2018;53:947–51.PubMedCrossRef
35.
Zurück zum Zitat Liu F, Ma R, Riordan SM, Grimm MC, Liu L, Wang Y, et al. Campylobacter, azathioprine, mercaptopurine, and 5-aminosalicylic acid affect the growth of IBD-associated species and other enteric microbes. Front Microbiol. 2017;8:527.PubMedPubMedCentral Liu F, Ma R, Riordan SM, Grimm MC, Liu L, Wang Y, et al. Campylobacter, azathioprine, mercaptopurine, and 5-aminosalicylic acid affect the growth of IBD-associated species and other enteric microbes. Front Microbiol. 2017;8:527.PubMedPubMedCentral
36.
Zurück zum Zitat Andrews CN, Griffiths TA, Kaufman J, Vergnolle N, Surette MG, Rioux KP. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34:374–83.PubMedCrossRef Andrews CN, Griffiths TA, Kaufman J, Vergnolle N, Surette MG, Rioux KP. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34:374–83.PubMedCrossRef
37.
Zurück zum Zitat Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–92.PubMedPubMedCentralCrossRef Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–92.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Anderson A, Click B, Ramos-Rivers C, Cheng D, Babichenko D, Koutroubakis IE, et al. Lasting impact of Clostridium difficile infection in inflammatory bowel disease: a propensity score matched analysis. Inflamm Bowel Dis. 2017;23:2180–8.PubMedCrossRef Anderson A, Click B, Ramos-Rivers C, Cheng D, Babichenko D, Koutroubakis IE, et al. Lasting impact of Clostridium difficile infection in inflammatory bowel disease: a propensity score matched analysis. Inflamm Bowel Dis. 2017;23:2180–8.PubMedCrossRef
39.
Zurück zum Zitat Khanna S. Management of Clostridioides difficile infection in patients with inflammatory bowel disease. Intest Res. 2021;19:265–74.PubMedCrossRef Khanna S. Management of Clostridioides difficile infection in patients with inflammatory bowel disease. Intest Res. 2021;19:265–74.PubMedCrossRef
40.
Zurück zum Zitat Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis. 2009;3:4–7.PubMedCrossRef Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis. 2009;3:4–7.PubMedCrossRef
41.
Zurück zum Zitat Oshima T, Wu L, Li M, Fukui H, Watari J, Miwa H. Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis. J Gastroenterol. 2018;53:84–94.PubMedCrossRef Oshima T, Wu L, Li M, Fukui H, Watari J, Miwa H. Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis. J Gastroenterol. 2018;53:84–94.PubMedCrossRef
42.
Zurück zum Zitat Chang TH, Hsu WY, Yang TI, Lu CY, Hsueh PP, Chen JM, et al. Increased age and proton pump inhibitors are associated with severe Clostridium difficile infections in children. J Microbiol Immunol Infect. 2020;53:578–84.PubMedCrossRef Chang TH, Hsu WY, Yang TI, Lu CY, Hsueh PP, Chen JM, et al. Increased age and proton pump inhibitors are associated with severe Clostridium difficile infections in children. J Microbiol Immunol Infect. 2020;53:578–84.PubMedCrossRef
43.
Zurück zum Zitat Naito Y, Kashiwagi K, Takagi T, Andoh A, Inoue R. Intestinal dysbiosis secondary to proton-pump inhibitor use. Digestion. 2018;97:195–204.PubMedCrossRef Naito Y, Kashiwagi K, Takagi T, Andoh A, Inoue R. Intestinal dysbiosis secondary to proton-pump inhibitor use. Digestion. 2018;97:195–204.PubMedCrossRef
44.
Zurück zum Zitat Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339–44.PubMedCrossRef Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339–44.PubMedCrossRef
45.
Zurück zum Zitat Trifan A, Stanciu C, Stoica O, Girleanu I, Cojocariu C. Impact of Clostridium difficile infection on inflammatory bowel disease outcome: a review. World J Gastroenterol. 2014;20:11736–42.PubMedPubMedCentralCrossRef Trifan A, Stanciu C, Stoica O, Girleanu I, Cojocariu C. Impact of Clostridium difficile infection on inflammatory bowel disease outcome: a review. World J Gastroenterol. 2014;20:11736–42.PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Oliva-Hemker M, Hutfless S, Al Kazzi ES, Lerer T, Mack D, LeLeiko N, et al. Clinical presentation and five-year therapeutic management of very early-onset inflammatory bowel disease in a large north American cohort. J Pediatr. 2015;167:527-32.e1-3.PubMedCrossRef Oliva-Hemker M, Hutfless S, Al Kazzi ES, Lerer T, Mack D, LeLeiko N, et al. Clinical presentation and five-year therapeutic management of very early-onset inflammatory bowel disease in a large north American cohort. J Pediatr. 2015;167:527-32.e1-3.PubMedCrossRef
47.
Zurück zum Zitat Sandberg KC, Davis MM, Gebremariam A, Adler J. Disproportionate rise in Clostridium difficile-associated hospitalizations among US youth with inflammatory bowel disease, 1997–2011. J Pediatr Gastroenterol Nutr. 2015;60:486–92.PubMedPubMedCentralCrossRef Sandberg KC, Davis MM, Gebremariam A, Adler J. Disproportionate rise in Clostridium difficile-associated hospitalizations among US youth with inflammatory bowel disease, 1997–2011. J Pediatr Gastroenterol Nutr. 2015;60:486–92.PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–10.PubMedCrossRef Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–10.PubMedCrossRef
49.
Zurück zum Zitat Chen Y, Furuya-Kanamori L, Doi SA, Ananthakrishnan AN, Kirk M. Clostridium difficile infection and risk of colectomy in patients with inflammatory bowel disease: a bias-adjusted meta-analysis. Inflamm Bowel Dis. 2017;23:200–7.PubMedCrossRef Chen Y, Furuya-Kanamori L, Doi SA, Ananthakrishnan AN, Kirk M. Clostridium difficile infection and risk of colectomy in patients with inflammatory bowel disease: a bias-adjusted meta-analysis. Inflamm Bowel Dis. 2017;23:200–7.PubMedCrossRef
Metadaten
Titel
Risk factors for Clostridioides difficile infection in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysis
verfasst von
Sheng-Bo Fang
Yan-Qing Song
Chun-Yan Zhang
Li-Bo Wang
Publikationsdatum
20.11.2021
Verlag
Springer Singapore
Erschienen in
World Journal of Pediatrics / Ausgabe 1/2022
Print ISSN: 1708-8569
Elektronische ISSN: 1867-0687
DOI
https://doi.org/10.1007/s12519-021-00486-1

Weitere Artikel der Ausgabe 1/2022

World Journal of Pediatrics 1/2022 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.